Form 8-K
8-K — Serina Therapeutics, Inc.
Accession: 0001708599-26-000060
Filed: 2026-10-09
Period: 2026-10-05
CIK: 0001708599
SIC: 2834 (PHARMACEUTICAL PREPARATIONS)
Item: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item: Financial Statements and Exhibits
Documents
8-K — ser-20261005.htm (Primary)
EX-3.1 (serinade-certificateofel.htm)
GRAPHIC (serinade-certificateofel001.jpg)
GRAPHIC (serinade-certificateofel002.jpg)
GRAPHIC (serinade-certificateofel003.jpg)
XML — IDEA: XBRL DOCUMENT (R1.htm)
8-K
8-K (Primary)
Filename: ser-20261005.htm · Sequence: 1
ser-20261005
000170859912/31false00017085992026-10-052026-10-0500017085992026-12-312026-12-31
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (date of earliest event reported): October 5, 2026
Serina Therapeutics, Inc.
(Exact name of registrant as specified in its charter)
Delaware 1-38519 82-1436829
(State or other jurisdiction
of incorporation) (Commission
File Number) (IRS Employer
Identification No.)
601 Genome Way, Suite 2001
Huntsville, Alabama 35806
(Address of principal executive offices)
(256) 327-9630
(Registrant’s telephone number, including area code)
Not applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class Trading Symbol Name of exchange on which registered
Common Stock, par value $0.0001 per share SER NYSE American
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.
On October 5, 2026, Serina Therapeutics, Inc. (the “Company”) filed a Certificate of Elimination (the “Certificate of Elimination”) with the Secretary of State of the State of Delaware, pursuant to Section 151(g) of the General Corporation Law of the State of Delaware, eliminating from the Company’s First Amended and Restated Certificate of Incorporation, as amended, all matters set forth in the Certificate of Designations of Preferences, Rights and Limitations of Series A Convertible Preferred Stock, filed with the Secretary of State of the State of Delaware on April 10, 2025, as corrected by the Certificate of Correction filed on May 22, 2025 (together, the “Certificate of Designations”), with respect to the Company’s Series A Convertible Preferred Stock, par value $0.0001 per share (the “Series A Preferred Stock”).
None of the shares of Series A Preferred Stock are outstanding, because all issued and outstanding shares of Series A Preferred Stock have been converted into shares of the Company’s common stock, and none will be issued subject to the Certificate of Designations. Upon the filing of the Certificate of Elimination, the shares previously designated as Series A Preferred Stock resumed the status of authorized but unissued shares of the Company’s preferred stock, without designation as to series.
The foregoing description of the Certificate of Elimination does not purport to be complete and is qualified in its entirety by reference to the full text of the Certificate of Elimination, a copy of which is attached as Exhibit 3.1 to this Current Report on Form 8-K and is incorporated herein by reference.
Item 9.01 - Financial Statements and Exhibits.
(d) Exhibits
Exhibit
Number Description
3.1
Certificate of Elimination of Series A Convertible Preferred Stock of Serina Therapeutics, Inc., filed with the Secretary of State of the State of Delaware on October 5, 2026.
104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
SERINA THERAPEUTICS, INC.
Date: October 9, 2026
By: /s/ Steve Ledger
Chief Executive Officer
EX-3.1
EX-3.1
Filename: serinade-certificateofel.htm · Sequence: 2
serinade-certificateofel
State of Delaware Secretary of State Division of Corporations Delh•ered 12 :22 P:\1 10/05/2026 FILED 12:22 PM 10/05/2026 SR 20264597278 - File Number 6241730 CERTIFICATE OF ELIMINATION OF SERIES A CONVERTIBLE PREFERRED STOCK OF SERINA THERAPEUTICS, INC. (Pursuant to Section 151 (g) of the General Corporation Law of the State of Delaware) Serina Therapeutics, Inc., a Delaware corporation (the "Company"), in accordance with the provisions of Section 151 (g) of the General Corporation Law of the State of Delaware (the "DGCL"), hereby certifies as follows: FIRST: That, pursuant to Section 151 of the DGCL and the authority granted in Section 4.2 of the Company's First Amended and Restated Certificate of Incorporation, as amended (the "Certificate of Incorporation"), the Board of Directors of the Company (the "Board"), by resolution duly adopted, authorized the issuance of a series of preferred stock of the Company designated as "Series A Convertible Preferred Stock," par value $0.0001 per share (the "Series A Preferred Stock"), consisting of 965 ,250 authorized shares, and established the voting powers, designations, preferences and relative, participating and other rights, and the qualifications, limitations and restrictions, of the Series A Preferred Stock, as set forth in the Certificate of Designations of Preferences, Rights and Limitations of Series A Convertible Preferred Stock of Serina Therapeutics, Inc., filed with the Secretary of State of the State of Delaware on April 10, 2025, as corrected by the Certificate of Correction of Serina Therapeutics, Inc. filed with the Secretary of State of the State of Delaware on May 22, 2025 (collectively, the "Certificate of Designations"). SECOND: That shares of Series A Preferred Stock were issued by the Company pursuant to the Certificate of Designations, and that all such issued and outstanding shares of Series A Preferred Stock have since been converted into shares of Common Stock of the Company. Accordingly, no shares of Series A Preferred Stock are outstanding, and no shares of Series A Preferred Stock will be issued subject to the Certificate of Designations. THIRD: That, on October 2, 2026, the Board duly adopted the following resolutions approving the elimination of the Series A Preferred Stock: "WHEREAS, pursuant to Section 151 of the General Corporation Law of the State of Delaware (the "DGCL") and the authority granted in the Company's First Amended and Restated Certificate of Incorporation, as amended (the "Certificate of Incorporation") , the Board previously authorized and designated 965 ,250 shares of the Company's preferred stock, par value $0.0001 per share, as "Series A Convertible Preferred Stock" (the "Series A Preferred Stock"), as set forth in the Certificate of Designations of Preferences, Rights and Limitations of Series A Convertible Preferred Stock of Serina Therapeutics, Inc. , filed with the Secretary of State of the State of Delaware on April 10, 2025 , as corrected by the Certificate of Correction of Serina Therapeutics, Inc. filed with the
Secretary of State of the State of Delaware on May 22 , 2025 (collectively, the "Certificate ofDesignations"); WHEREAS, all issued and outstanding shares of Series A Preferred Stock have been converted into shares of the Company's Common Stock and, as of the date hereof, no shares of Series A Preferred Stock are issued and outstanding, and no shares of Series A Preferred Stock will be issued subject to the Certificate of Designations; and WHEREAS, the Board deems it advisable and in the best interests of the Company and its stockholders that all matters set forth in the Certificate of Designations with respect to the Series A Preferred Stock be eliminated from the Certificate oflncorporation, and that such shares resume the status of authorized but unissued shares of preferred stock of the Company, without designation as to series. NOW, THEREFORE, BE IT RESOLVED, that no shares of the Company's Series A Convertible Preferred Stock, par value $0.0001 per share, are issued and outstanding, and no shares of Series A Preferred Stock will be issued subject to the Certificate of Designations; RESOLVED FURTHER, that the Board hereby approves and declares it advisable that the Certificate of Designations, and all matters set forth therein with respect to the Series A Preferred Stock, be eliminated in their entirety from the Certificate of Incorporation pursuant to Section 151 (g) of the DGCL, and that the shares of preferred stock previously designated as Series A Preferred Stock resume the status of authorized but unissued shares of preferred stock of the Company, without designation as to series; RESOLVED FURTHER, that the Chief Executive Officer and Chief Financial Officer of the Company ( each, an "Authorized Officer") be, and each of them individually hereby is, authorized, empowered and directed, in the name and on behalf of the Company, to prepare, execute, acknowledge, deliver and file with the Secretary of State of the State of Delaware a Certificate of Elimination with respect to the Series A Preferred Stock, pursuant to Section 15 l(g) of the DGCL, setting forth these resolutions, substantially in the form presented to and reviewed by the Board, with such changes thereto as any Authorized Officer executing the same shall approve, such Authorized Officer's execution and delivery thereof to be conclusive evidence of such approval; RESOLVED FURTHER, that, upon the filing and effectiveness of such Certificate of Elimination, all matters set forth in the Certificate of Designations with respect to the Series A Preferred Stock shall be eliminated from the Company's Certificate oflncorporation; 2
Docuslgn Envelope ID: 39E40FD4-C7DF-817A-8322-7B706995F836 RESOLVED FURTHER, that each Authorized Officer be, and each of them individually hereby is, authorized and directed to take any and all further action, and to execute and deliver any and all further agreements, documents, certificates and instruments, in the name and on behalf of the Company, as such officer may deem necessary, desirable or appropriate to carry out the intent and purposes of the foregoing resolutions, the taking of any such action or the execution of any such document by such officer to be conclusive evidence of such officer's authority to do so; and RESOLVED FURTHER, that all actions heretofore taken by any officer, director, or agent of the Company in connection with the matters contemplated by the foregoing resolutions be, and the same hereby are, ratified, confirmed, and approved in all respects." FOURTH: That, pursuant to the provisions of Section 151(g) of the DGCL, all matters set forth in the Certificate of Designations with respect to the Series A Preferred Stock are hereby eliminated from the Certificate oflncorporation, and the shares that were designated as Series A Preferred Stock are hereby returned to the status of authorized but unissued shares of preferred stock of the Company, without designation as to series. IN WITNESS WHEREOF, the Company has caused this Certificate of Elimination to be executed by its duly authorized officer on this 2nd day of October, 2026. SERINA THERAPEUTICS, INC., a Delaware corporation s~ l),,J_,p- By: _____________ _ Steve Ledger As Chief Executive Officer 3
GRAPHIC
GRAPHIC
Filename: serinade-certificateofel001.jpg · Sequence: 6
Binary file (227553 bytes)
Download serinade-certificateofel001.jpg
GRAPHIC
GRAPHIC
Filename: serinade-certificateofel002.jpg · Sequence: 7
Binary file (200146 bytes)
Download serinade-certificateofel002.jpg
GRAPHIC
GRAPHIC
Filename: serinade-certificateofel003.jpg · Sequence: 8
Binary file (127631 bytes)
Download serinade-certificateofel003.jpg
XML — IDEA: XBRL DOCUMENT
XML
Filename: R1.htm · Sequence: 10
v3.26.3
Cover
Dec. 31, 2026
Oct. 05, 2026
Cover [Abstract]
Document Type
8-K
Document Period End Date
Oct. 05, 2026
Entity Registrant Name
Serina Therapeutics, Inc.
Entity Incorporation, State or Country Code
DE
Entity File Number
1-38519
Entity Tax Identification Number
82-1436829
Entity Address, Address Line One
601 Genome Way
Entity Address, Address Line Two
Suite 2001
Entity Address, City or Town
Huntsville
Entity Address, State or Province
AL
Entity Address, Postal Zip Code
35806
City Area Code
(256)
Local Phone Number
327-9630
Written Communications
false
Soliciting Material
false
Pre-commencement Tender Offer
false
Pre-commencement Issuer Tender Offer
false
Title of 12(b) Security
Common Stock, par value $0.0001 per share
Trading Symbol
SER
Security Exchange Name
NYSEAMER
Entity Emerging Growth Company
false
Entity Central Index Key
0001708599
Current Fiscal Year End Date
--12-31
Amendment Flag
false
X
- Definition
Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
No definition available.
+ Details
Name:
dei_AmendmentFlag
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Area code of city
+ References
No definition available.
+ Details
Name:
dei_CityAreaCode
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Cover page.
+ References
No definition available.
+ Details
Name:
dei_CoverAbstract
Namespace Prefix:
dei_
Data Type:
xbrli:stringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
End date of current fiscal year in the format --MM-DD.
+ References
No definition available.
+ Details
Name:
dei_CurrentFiscalYearEndDate
Namespace Prefix:
dei_
Data Type:
xbrli:gMonthDayItemType
Balance Type:
na
Period Type:
duration
X
- Definition
For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
No definition available.
+ Details
Name:
dei_DocumentPeriodEndDate
Namespace Prefix:
dei_
Data Type:
xbrli:dateItemType
Balance Type:
na
Period Type:
duration
X
- Definition
The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
No definition available.
+ Details
Name:
dei_DocumentType
Namespace Prefix:
dei_
Data Type:
dei:submissionTypeItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Address Line 1 such as Attn, Building Name, Street Name
+ References
No definition available.
+ Details
Name:
dei_EntityAddressAddressLine1
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Address Line 2 such as Street or Suite number
+ References
No definition available.
+ Details
Name:
dei_EntityAddressAddressLine2
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Name of the City or Town
+ References
No definition available.
+ Details
Name:
dei_EntityAddressCityOrTown
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Code for the postal or zip code
+ References
No definition available.
+ Details
Name:
dei_EntityAddressPostalZipCode
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Name of the state or province.
+ References
No definition available.
+ Details
Name:
dei_EntityAddressStateOrProvince
Namespace Prefix:
dei_
Data Type:
dei:stateOrProvinceItemType
Balance Type:
na
Period Type:
duration
X
- Definition
A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityCentralIndexKey
Namespace Prefix:
dei_
Data Type:
dei:centralIndexKeyItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Indicate if registrant meets the emerging growth company criteria.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityEmergingGrowthCompany
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
No definition available.
+ Details
Name:
dei_EntityFileNumber
Namespace Prefix:
dei_
Data Type:
dei:fileNumberItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Two-character EDGAR code representing the state or country of incorporation.
+ References
No definition available.
+ Details
Name:
dei_EntityIncorporationStateCountryCode
Namespace Prefix:
dei_
Data Type:
dei:edgarStateCountryItemType
Balance Type:
na
Period Type:
duration
X
- Definition
The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityRegistrantName
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityTaxIdentificationNumber
Namespace Prefix:
dei_
Data Type:
dei:employerIdItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Local phone number for entity.
+ References
No definition available.
+ Details
Name:
dei_LocalPhoneNumber
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 13e
-Subsection 4c
+ Details
Name:
dei_PreCommencementIssuerTenderOffer
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 14d
-Subsection 2b
+ Details
Name:
dei_PreCommencementTenderOffer
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Title of a 12(b) registered security.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b
+ Details
Name:
dei_Security12bTitle
Namespace Prefix:
dei_
Data Type:
dei:securityTitleItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Name of the Exchange on which a security is registered.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection d1-1
+ Details
Name:
dei_SecurityExchangeName
Namespace Prefix:
dei_
Data Type:
dei:edgarExchangeCodeItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 14a
-Subsection 12
+ Details
Name:
dei_SolicitingMaterial
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Trading symbol of an instrument as listed on an exchange.
+ References
No definition available.
+ Details
Name:
dei_TradingSymbol
Namespace Prefix:
dei_
Data Type:
dei:tradingSymbolItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Securities Act
-Number 230
-Section 425
+ Details
Name:
dei_WrittenCommunications
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration